Welcome to our dedicated page for Aquestive Therapeutics SEC filings (Ticker: AQST), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Aquestive Therapeutics, Inc. filings document the regulatory, financial, governance, and capital-structure disclosures of a specialty pharmaceutical company built around oral-film drug delivery, proprietary product candidates, and CDMO/licensee manufacturing. Its 8-K reports include FDA communications and Regulation FD materials for Anaphylm™, financial results, investor presentations, and material agreements related to revenue-sharing, warrants, and common-stock purchase commitments.
Proxy materials describe annual-meeting voting matters, director elections, executive compensation, auditor ratification, and board governance. Other current reports record officer-transition matters, compensatory arrangements, exhibits, and product-development updates tied to the company’s regulatory strategy.
Aquestive Therapeutics reported that Chief Legal Officer Thomas A. Zalewski received equity-based compensation. He was granted 100,000 shares of restricted Common Stock, which will vest in three annual installments of 25%, 25%, and 50%. He also received a Non-Qualified Stock Option for 75,000 shares of Common Stock at an exercise price of $4.135 per share, vesting on the same 25%/25%/50% schedule and expiring in 2036. After these awards, his reported holdings from this grant are 100,000 shares of Common Stock and options for 75,000 underlying shares.
Aquestive Therapeutics President and CEO Daniel Barber reported an open-market sale of 8,257 shares of Common Stock. The weighted average sale price was $4.2889 per share, with individual trades ranging from $4.17 to $4.64. After this transaction, he directly holds 660,574 shares.
Aquestive Therapeutics, Inc. executive Melina Cioffi, SVP of Regulatory Affairs, reported a routine tax-related share disposition. On the transaction date, 1,667 shares of common stock were withheld by the company at $4.17 per share to cover tax obligations from vesting RSUs. After this withholding, Cioffi directly holds 273,200 shares of common stock, indicating the event is part of equity compensation mechanics rather than an open-market sale.
AQST-related Rule 144 notice: a broker-dealer filing lists proposed or recent sales of Common Stock linked to restricted stock units and prior dispositions. The excerpt shows 180,677 shares sold on 03/10/2026 for $753,965.12. The filing references 125,450,119 shares outstanding as of 05/15/2026.
The filing names Morgan Stanley Smith Barney LLC Executive Financial Services as broker-dealer and reports an entry for Daniel R. Barber. Timing and exact quantity offered under Rule 144 in this excerpt beyond the sold shares are not detailed.
Aquestive Therapeutics reported stronger Q1 2026 results with higher revenue and a smaller loss. Revenue rose to $14,446 from $8,720 a year earlier, driven by manufacture and supply activity and $4,500 of royalty revenue from Zevra. The net loss narrowed to $8,057 from $22,930, helped by lower R&D and selling, general and administrative costs. Cash and cash equivalents were $110,734 as of March 31, 2026, against total liabilities of $175,179, leaving stockholders’ deficit at $34,054. The company continued to use its at-the-market equity program, raising about $4,810 net in the quarter, and carries $45,000 of 13.5% Senior Secured Notes and royalty obligations tied to future sales of Anaphylm and Libervant. Management believes current cash, reduced spending and access to equity markets are sufficient to fund operations for at least the next twelve months.
Aquestive Therapeutics reported a much stronger first quarter of 2026 and refinanced its capital structure to support its lead allergy drug, Anaphylm. Total revenue rose to $14.4 million from $8.7 million, driven by higher license, royalty, and manufacturing revenue. Net loss narrowed sharply to $8.1 million, or $0.07 per share, compared with a $22.9 million loss a year earlier, helped by lower R&D and SG&A expenses. Non-GAAP adjusted EBITDA loss improved to $1.7 million from $17.6 million. The company ended the quarter with $110.7 million in cash and reaffirmed 2026 guidance for revenue of $46–$50 million and non-GAAP adjusted EBITDA loss of $30–$35 million. Separately, Aquestive entered a new five-year $150 million term loan facility with Oaktree, including $55 million funded at closing to refinance $45 million of existing notes, interest-only payments until 2031 maturity, and additional tranches tied to FDA approval and sales milestones for Anaphylm.
Aquestive Therapeutics Corporate Secretary reports routine tax withholding transaction. On the disposition date, 135,690 shares of common stock were withheld by the company to cover Lori J. Braender’s tax withholding obligation related to vesting Restricted Stock Units. After this non-market transaction, she directly holds 231,042 shares of common stock.
Aquestive Therapeutics Chief People Officer Peter E. Boyd reported a tax-related share disposition tied to equity compensation. On the vesting of previously granted Performance Stock Units, 56,778 shares of common stock were withheld by Aquestive to cover his tax withholding obligation at $4.18 per share.
After this tax withholding event, Boyd directly holds 281,731 shares of Aquestive Therapeutics common stock. The transaction was coded as a tax-withholding disposition (code F), indicating an administrative settlement of taxes rather than an open-market trade.
Aquestive Therapeutics President and CEO Daniel Barber reported a compensation-related share adjustment. On the vesting of previously granted Performance Stock Units, the company withheld 335,922 shares of common stock at $4.18 per share to cover his tax withholding obligation. After this tax-withholding disposition, Barber directly owns 668,831 common shares, and the filing shows no remaining derivative positions.
Aquestive Therapeutics, Inc. Chief Financial Officer Ernest A. Toth Jr. reported a routine tax-related share disposition. On May 5, 2026, 92,652 shares of common stock were withheld at $4.18 per share to cover taxes on vesting Performance Stock Units. After this withholding, he continues to directly hold 283,460 shares of Aquestive common stock.